These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29666602)

  • 1. Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma.
    Montes V; Sousa S; Pita F; Guerreiro R; Carmona C
    Front Neurol; 2018; 9():150. PubMed ID: 29666602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.
    Liao B; Shroff S; Kamiya-Matsuoka C; Tummala S
    Neuro Oncol; 2014 Apr; 16(4):589-93. PubMed ID: 24482447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.
    Derle E; Benli S
    Neurol Sci; 2018 Oct; 39(10):1773-1774. PubMed ID: 29948466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ipilimumab as a Cause of Severe Pan-Colitis and Colonic Perforation.
    Shah R; Witt D; Asif T; Mir FF
    Cureus; 2017 Apr; 9(4):e1182. PubMed ID: 28533998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis.
    Yu C; Chopra IJ; Ha E
    Endocrinol Diabetes Metab Case Rep; 2015; 2015():140092. PubMed ID: 25759760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Severe Myositis, Myocarditis, and Myasthenia Gravis with Elevated Anti-Striated Muscle Antibody following Single Dose of Ipilimumab-Nivolumab Therapy in a Patient with Metastatic Melanoma.
    Fazel M; Jedlowski PM
    Case Reports Immunol; 2019; 2019():2539493. PubMed ID: 31183226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab-induced myasthenia gravis: A fatal case report.
    March KL; Samarin MJ; Sodhi A; Owens RE
    J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors.
    Makarious D; Horwood K; Coward JIG
    Eur J Cancer; 2017 Sep; 82():128-136. PubMed ID: 28666240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab for advanced melanoma: a nursing perspective.
    Ledezma B
    Oncol Nurs Forum; 2009 Jan; 36(1):97-104. PubMed ID: 19136343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab-Induced Enteritis without Colitis: A New Challenge.
    Messmer M; Upreti S; Tarabishy Y; Mazumder N; Chowdhury R; Yarchoan M; Holdhoff M
    Case Rep Oncol; 2016; 9(3):705-713. PubMed ID: 27920706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab.
    Lau KH; Kumar A; Yang IH; Nowak RJ
    Muscle Nerve; 2016 Jun; 54(1):157-61. PubMed ID: 27065302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoimmune myositis and myasthenia gravis resulting from a combination therapy with nivolumab and ipilimumab for metastatic melanoma.
    Sutaria R; Patel P; Danve A
    Eur J Rheumatol; 2019 Jul; 6(3):153-154. PubMed ID: 30986169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
    Camacho LH
    Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
    JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma.
    Zibelman M; Olszanski AJ
    J Natl Compr Canc Netw; 2014 Oct; 12(12 Suppl 2):S1-S5. PubMed ID: 31094496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unusual pulmonary toxicity of ipilimumab treated by macrolides.
    Mailleux M; Cornélis F; Colin GC; Baurain JF
    Acta Clin Belg; 2015 Dec; 70(6):442-4. PubMed ID: 26790556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
    Werner JM; Schweinsberg V; Schroeter M; von Reutern B; Malter MP; Schlaak M; Fink GR; Mauch C; Galldiks N
    Front Oncol; 2019; 9():84. PubMed ID: 30828569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Myasthenia gravis induced by inmuno checkpoints inhibitors: first case report secondary to avelumab therapy and review of published cases].
    Reyes-Bueno JA; Rodriguez-Santos L; Serrano-Castro PJ
    Rev Neurol; 2019 Apr; 68(8):333-338. PubMed ID: 30963530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.